Ted W. Johnson

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Paul Richardson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 571 citations · Full text

Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission

Smruthi Karthikeyan, Joshua I. Levy, Peter De Hoff et al. · Nature · 2022 · 482 citations · Full text

Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F

Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner et al. · New England Journal of Medicine · 2015 · 479 citations · Full text

Oncogenic Agent, Medicine, Genetics +15

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 456 citations · Full text

Drug Target, Health Sciences, Preclinical Models +10

Using the Golden Triangle to optimize clearance and oral absorption

Ted W. Johnson, Klaus Dress, Martin P. Edwards · Bioorganic & Medicinal Chemistry Letters · 2009 · 362 citations

Golden Triangle, Medicine, Oral Cavity +4